Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?

被引：3
|
作者：
Hill, A [1 ]
机构：
[1] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
来源：
AIDS | 2005年 / 19卷 / 17期
关键词：
D O I：
10.1097/01.aids.0000194137.73876.d5
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2054 / 2055
页数：2
相关论文
共 50 条
  • [31] Kaletra (lopinavir/ritonavir)
    Corbett, AH
    Lim, ML
    Kashuba, ADM
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (7-8) : 1193 - 1203
  • [32] Lopinavir/Ritonavir in Pregnancy
    Roberts, Susan S.
    Martinez, Marisol
    Covington, Deborah L.
    Rode, Richard A.
    Pasley, Mary V.
    Woodward, William C.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (04) : 456 - 461
  • [33] Monotherapy with lopinavir/ritonavir
    Schechter, Mauro
    Nunes, Estevao Portela
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (05) : 735 - 741
  • [34] Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir
    Martinez, E.
    Gonzalez-Cordon, A.
    Ferrer, E.
    Domingo, P.
    Negredo, E.
    Gutierrez, F.
    Portilla, J.
    Curran, A.
    Podzamczer, D.
    Murillas, J.
    Bernardino, J. I.
    Santos, I.
    Carton, J. A.
    Peraire, J.
    Pich, J.
    Perez, I.
    Gatell, J. M.
    HIV MEDICINE, 2014, 15 (06) : 330 - 338
  • [35] Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin
    Busti, Anthony J.
    Bain, Amy M.
    Hall, Ronald G., II
    Bedimo, Roger G.
    Leff, Richard D.
    Meek, Claudia
    Mehvar, Reza
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2008, 51 (06) : 605 - 610
  • [36] Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study
    Keiser, Philip H.
    Nassar, Naiel
    INTERNATIONAL JOURNAL OF STD & AIDS, 2008, 19 (08) : 561 - 562
  • [37] The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis
    Abou-El-Naga, Iman Fathy
    El Kerdany, Eman Dorry
    Mady, Rasha Fadly
    Shalaby, Thanaa Ibrahim
    Zaytoun, Enas Mohammed
    PARASITOLOGY INTERNATIONAL, 2017, 66 (06) : 735 - 747
  • [38] Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir
    Rockwood, Neesha
    Mandalia, Sundhiya
    Bower, Mark
    Gazzard, Brian
    Nelson, Mark
    AIDS, 2011, 25 (13) : 1671 - 1673
  • [39] Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults
    Ferrer, Elena
    del Rio, Luis
    Martinez, Esteban
    Curto, Jordi
    Domingo, Pere
    Ribera, Esteban
    Negredo, Eugenia
    Rosales, Joaquim
    Saumoy, Maria
    Ordonez, Jordi
    Gatell, Josep M.
    Podzamczer, Daniel
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : 1061 - 1065
  • [40] Atazanavir/ritonavir versus Lopinavir/ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis
    Tigabu, Bereket Molla
    Agide, Feleke Doyore
    Mohraz, Minoo
    Nikfar, Shekoufeh
    AFRICAN HEALTH SCIENCES, 2020, 20 (01) : 91 - 101
12345